Physician profile
David A Lee
NPI 1104840016
$17,036.47
in general payments reported to CMS, 2019-2025
20 companies · $669 in 2025
The $669 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,449 · 2020: $4,986 · 2021: $685 · 2022: $287 · 2023: $716 · 2024: $244 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14,072.15 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $473.48 | 2022-2024 | Miebo, Vyzulta, Xiidra |
| Allergan, INC. | $384.27 | 2019 | |
| New World Medical,INC. | $374.69 | 2023-2025 | Streamline, Clearpath, Via360 |
| Lumenis Be INC | $321.46 | 2025 | M22 |
| Aerie Pharmaceuticals, INC. | $259.45 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $238.47 | 2019-2023 | Eylea |
| Oyster Point Pharma, INC. | $181.71 | 2022-2023 | Tyrvaya |
| Genentech USA, INC. | $118.48 | 2022 | |
| Horizon Therapeutics Plc | $115.19 | 2023 | Tepezza |
| Eyepoint US, INC. | $111.45 | 2021 | |
| Spark Therapeutics, INC. | $81.82 | 2019 | |
| Ethicon US, LLC | $81.25 | 2025 | Echelon; Endopath, Harmonic |
| Maculogix, INC. | $50.00 | 2019 | |
| Ocular Therapeutix, INC. | $49.97 | 2023 | Dextenza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $34.52 | 2025 | Xdemvy |
| Abbvie INC. | $32.07 | 2024 | |
| Alcon Vision LLC | $31.70 | 2019-2022 | |
| Glaukos Corporation | $12.61 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.